Literature DB >> 16214228

Development and application of a quantitative RT-PCR potency assay for a pentavalent rotavirus vaccine (RotaTeq).

Todd Ranheim1, Pamela K Mathis, Daniel B Joelsson, Mary Ellen Smith, Kathryn M Campbell, Gwendolyn Lucas, Scott Barmat, Erin Melissen, Robert Benz, John A Lewis, Jie Chen, Timothy Schofield, Robert D Sitrin, John P Hennessey.   

Abstract

A sensitive and reproducible method to determine the in vitro infectious potency of a pentavalent reassortant rotavirus vaccine (RotaTeq) has been developed as an alternative to classical potency assays. Potency was determined based on cell-based viral replication followed by quantitative reverse-transcription polymerase chain reaction (RT-QPCR) analysis. In the assay, confluent Vero cell monolayers in 96-well plates were inoculated with serial dilutions of test samples, a pentavalent reassortant rotavirus reference standard and assay controls, followed by incubation for 24h. The cells were lysed with a Triton X-100 solution and the lysates assayed by RT-QPCR to quantitate viral nucleic acid produced during replication. The RT-QPCR utilizes primer/probe sets specific to each virus reassortant and the potencies of each sample were determined relative to the reference standard. This assay, hereafter referred to as the Multivalent QPCR-Based Potency Assay (M-QPA), permits the specific quantitation of each individual reassortant virus in the presence of the other four reassortant viruses. In addition, the assay was demonstrated to be concordant with a traditional method (plaque assay) for the quantitation of infectious virus particles. It is anticipated that assays of this type will become a valuable tool in the assignment of potency values and in the monitoring of stability of live virus vaccines.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16214228     DOI: 10.1016/j.jviromet.2005.08.013

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  7 in total

1.  A TaqMan reverse transcription polymerase chain reaction (RT-PCR) in vitro potency assay for plasmid-based vaccine products.

Authors:  Rohit Mahajan; Beth Feher; Basil Jones; Doug Jones; Lana Marjerison; Mindy Sam; Jukka Hartikka; Mary Wloch; Peggy Lalor; David Kaslow; Keith Hall; Alain Rolland
Journal:  Mol Biotechnol       Date:  2008-03-26       Impact factor: 2.695

2.  Development of one-step real-time PCR assay for titrating trivalent live attenuated influenza vaccines.

Authors:  Yang Zang; Dongchuan Du; Peng Ge; Yongqing Xu; Xintao Liu; Yan Zhang; Weiheng Su; Irina Kiseleva; Larisa Rudenko; Fei Xu; Wei Kong; Chunlai Jiang
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

3.  Formulation development of a live attenuated human rotavirus (RV3-BB) vaccine candidate for use in low- and middle-income countries.

Authors:  Prashant Kumar; Ravi S Shukla; Ashaben Patel; Swathi R Pullagurla; Christopher Bird; Oluwadara Ogun; Ozan S Kumru; Ahd Hamidi; Femke Hoeksema; Christopher Yallop; Julie E Bines; Sangeeta B Joshi; David B Volkin
Journal:  Hum Vaccin Immunother       Date:  2021-04-16       Impact factor: 3.452

4.  Evaluation of infectious titer in a candidate HSV type 2 vaccine by a quantitative molecular approach.

Authors:  Ali Azizi; Mei Tang; Lucy Gisonni-Lex; Laurent Mallet
Journal:  BMC Microbiol       Date:  2013-12-06       Impact factor: 3.605

5.  Rational design of heat stable lyophilized rotavirus vaccine formulations.

Authors:  Madhu Madan; Deepa Sikriwal; Gaurav Sharma; Nidhi Shukla; Ashwani Kumar Mandyal; Sachin Kale; Davinder Gill
Journal:  Hum Vaccin Immunother       Date:  2018-07-11       Impact factor: 3.452

Review 6.  Considerations for bioanalytical characterization and batch release of COVID-19 vaccines.

Authors:  Gautam Sanyal; Anna Särnefält; Arun Kumar
Journal:  NPJ Vaccines       Date:  2021-04-13       Impact factor: 7.344

7.  Real-time RT-PCR assays to differentiate wild-type group A rotavirus strains from Rotarix(®) and RotaTeq(®) vaccine strains in stool samples.

Authors:  Rashi Gautam; Mathew D Esona; Slavica Mijatovic-Rustempasic; Ka Ian Tam; Jon R Gentsch; Michael D Bowen
Journal:  Hum Vaccin Immunother       Date:  2013-12-16       Impact factor: 3.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.